Monday, 21 September 2009

Cobra takes loans to address shortfall

Cobra Biomanufacturing has taken a £180,000 loan from Sultan Scientific and a £50,000 loan from its biggest shareholder to fund its working capital shortfall.

Friday, 18 September 2009

Angel sales increase in H1

Angel Biotechnology reported stronger revenues in H1 2009 compared to 2008. Revenues grew 25% and the company signed contracts worth £2.2m in the half year ended 30 June. However, losses for the six-months also increased.

Codexis closes German site

Codexis has closed its Jülich, Germany, site as part of a move to streamline its supply chain efficiency. The company said it would continue to supply its inventory through a soon-to-be-launched e-store. Codexis acquired the Jülich site as part of its 2005 purchase of Jülich Fine Chemicals.

Novasep's Le Mans, France, HPAI facility gains SafeBridge certification

PR Newswire

PCAS sees first half sales decline 18%


Monday, 14 September 2009

Phoenix rises from Shasun

Phoenix Chemicals has purchased the Annan, Scotland, facility from Shasun. Shasun closed the facility in March. Phoenix said the former GlaxoSmithKline facility will expand its capabilities to manufacturing scale and plans to offer jobs to former site workers
Annandale Observer

Dishman looks to expand overseas

Dishman is expanding its contract research and manufacturing operations into Japan and the US. Dishman cfo, VVS Murthy, said the company is eyeing contracts in the US market and expects them to materialise in the financial year 2010-11.
DNA India

Informex 2010 registration is now open


Aesica will provide production and packaging for a number of Amdipharm products

In-Pharma Technologist

Angel Biotechnology will manufacture a second-generation formulation of ReNeuron’s lead CTX stem cell line for pre-clinical and clinical applications


Socma President, Joe Acker, to retire in December


Thursday, 3 September 2009

Almac founder establishes research charity

Almac founder Sir Allen McClay has established the McClay Foundation to fund research and commercial innovation in the field of healthcare and allied technologies. Almac will become the engine to generate funds for the foundation from the profits of its research and global sales.
Belfast Newsletter

Wednesday, 2 September 2009

Chinese FDA to introduce new GMP guidelines

China Financial Daily

SynCo in Japan deal

SynCo Bio Partners will provide process development and manufacturing for an unnamed Japanese company. SynCo will assist its client with in-house process development prior to transfer, scale-up and GMP manufacture for Phase I clinical trials in Amsterdam.

Indian appeals court decision will allow CMOs in India to claim tax credit on their advertising spend

Outsourcing Pharma

FDA expected to require manufacturing info in applications

The US FDA is expected to require more manufacturing site information on drug product applications. Edwin Rivera-Martinez, the FDA's chief of the international compliance in CDER’s manufacturing division said the rule is designed to cut down on unneeded FDA inspections and erroneous information about manufacturing sites by requiring sponsors to list establishments and locations involved in manufacturing drug products. Rivera-Martinez also said the agency will double its overseas inspections of facilities for GMP compliance this year from 50 to 100.
FDA News
FDA News

Lonza sells Singapore plant to Roche

Roche subsidiary Genentech has picked up its option to purchase a biologics manufacturing plant from Lonza. The facility will be merged with Genentech's existing facility in Singapore. Lonza will receive $290m and up to $70m in milestone payments.
In-pharma Technologist

Tuesday, 1 September 2009

Patheon continues to explore Lonza bid

Patheon's independent directors are continuing to examine Lonza's bid for the company. The Lonza offer, which is a 77% premium over that of JLL is conditional on being able to secure two-thirds of Patheon's shares.

Cobra struggles with cash; passes MHRA inspection

Despite an order book worth £10m Cobra Biomanufacturing's ability to continue as a going concern remains dependent on thecompany delivering contract signatures and converting these contracts into revenue and cash receipts. The company said trading conditions have resulted in a delay in the achievement of some contract signatures. Cobra has completed a successful cGMP audit by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) at its facility based at Keele.
Small Cap News